These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 32060789)

  • 21. Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses.
    Jiang S; Hillyer C; Du L
    Trends Immunol; 2020 May; 41(5):355-359. PubMed ID: 32249063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Why do children seem to be more protected against COVID-19? A hypothesis.
    Sposato B; Scalese M
    Med Hypotheses; 2020 Oct; 143():110151. PubMed ID: 32763661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness.
    Ralph R; Lew J; Zeng T; Francis M; Xue B; Roux M; Toloue Ostadgavahi A; Rubino S; Dawe NJ; Al-Ahdal MN; Kelvin DJ; Richardson CD; Kindrachuk J; Falzarano D; Kelvin AA
    J Infect Dev Ctries; 2020 Jan; 14(1):3-17. PubMed ID: 32088679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion.
    Xia S; Liu M; Wang C; Xu W; Lan Q; Feng S; Qi F; Bao L; Du L; Liu S; Qin C; Sun F; Shi Z; Zhu Y; Jiang S; Lu L
    Cell Res; 2020 Apr; 30(4):343-355. PubMed ID: 32231345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2: Zoonotic origin of pandemic coronavirus.
    Vilcek S
    Acta Virol; 2020; 64(3):281-287. PubMed ID: 32985202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Immune Response and Immunopathology of COVID-19.
    Mortaz E; Tabarsi P; Varahram M; Folkerts G; Adcock IM
    Front Immunol; 2020; 11():2037. PubMed ID: 32983152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody.
    Tian X; Li C; Huang A; Xia S; Lu S; Shi Z; Lu L; Jiang S; Yang Z; Wu Y; Ying T
    Emerg Microbes Infect; 2020; 9(1):382-385. PubMed ID: 32065055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.
    Gu H; Chen Q; Yang G; He L; Fan H; Deng YQ; Wang Y; Teng Y; Zhao Z; Cui Y; Li Y; Li XF; Li J; Zhang NN; Yang X; Chen S; Guo Y; Zhao G; Wang X; Luo DY; Wang H; Yang X; Li Y; Han G; He Y; Zhou X; Geng S; Sheng X; Jiang S; Sun S; Qin CF; Zhou Y
    Science; 2020 Sep; 369(6511):1603-1607. PubMed ID: 32732280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.
    Wang F; Kream RM; Stefano GB
    Med Sci Monit; 2020 May; 26():e924700. PubMed ID: 32366816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A pneumonia outbreak associated with a new coronavirus of probable bat origin.
    Zhou P; Yang XL; Wang XG; Hu B; Zhang L; Zhang W; Si HR; Zhu Y; Li B; Huang CL; Chen HD; Chen J; Luo Y; Guo H; Jiang RD; Liu MQ; Chen Y; Shen XR; Wang X; Zheng XS; Zhao K; Chen QJ; Deng F; Liu LL; Yan B; Zhan FX; Wang YY; Xiao GF; Shi ZL
    Nature; 2020 Mar; 579(7798):270-273. PubMed ID: 32015507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent advances of therapeutic targets and potential drugs of COVID-19.
    Zhang W; Zhang P; Wang G; Cheng W; Chen J; Zhang X
    Pharmazie; 2020 May; 75(5):161-163. PubMed ID: 32393419
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How obesity could create problems for a COVID vaccine.
    Ledford H
    Nature; 2020 Oct; 586(7830):488-489. PubMed ID: 33082543
    [No Abstract]   [Full Text] [Related]  

  • 33. Update of the current knowledge on genetics, evolution, immunopathogenesis, and transmission for coronavirus disease 19 (COVID-19).
    Tizaoui K; Zidi I; Lee KH; Ghayda RA; Hong SH; Li H; Smith L; Koyanagi A; Jacob L; Kronbichler A; Shin JI
    Int J Biol Sci; 2020; 16(15):2906-2923. PubMed ID: 33061805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The First 75 Days of Novel Coronavirus (SARS-CoV-2) Outbreak: Recent Advances, Prevention, and Treatment.
    Yan Y; Shin WI; Pang YX; Meng Y; Lai J; You C; Zhao H; Lester E; Wu T; Pang CH
    Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235575
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?
    Henrickson SE
    Sci Immunol; 2020 Apr; 5(46):. PubMed ID: 32245885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China.
    Yu F; Du L; Ojcius DM; Pan C; Jiang S
    Microbes Infect; 2020 Mar; 22(2):74-79. PubMed ID: 32017984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development.
    Ma C; Su S; Wang J; Wei L; Du L; Jiang S
    Microbes Infect; 2020; 22(6-7):245-253. PubMed ID: 32437926
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Genomic analysis of a 2019-novel coronavirus (2019-nCoV) strain in the first COVID-19 patient found in Hangzhou].
    Yu H; Wang XC; Li J; Qian X; Yu XF; Sun Z; Chen JF; Kao QJ; Wang HQ; Pan JC
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 May; 54(5):486-490. PubMed ID: 32171191
    [No Abstract]   [Full Text] [Related]  

  • 39.
    Lee CH; Koohy H
    F1000Res; 2020; 9():145. PubMed ID: 32269766
    [No Abstract]   [Full Text] [Related]  

  • 40. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes.
    Nikolich-Zugich J; Knox KS; Rios CT; Natt B; Bhattacharya D; Fain MJ
    Geroscience; 2020 Apr; 42(2):505-514. PubMed ID: 32274617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.